Industries de la santé
ARRAY BIOPHARMA AND PIERRE FABRE TO PRESENT PHASE 3 COLUMBUS TRIAL AT SOCIETY FOR MELANOMA RESEARCH ANNUAL CONGRESS
![Envoyer](/templates/yoo_flux/images/emailButton.png)
![Imprimer](/templates/yoo_flux/images/printButton.png)
![PDF](/templates/yoo_flux/images/pdf_button.png)
26 Octobre 2016
Boulder, Colo., and Castres, France (October 25, 2016) - Array BioPharma (NASDAQ: ARRY) and Pierre Fabre announced today that results from the Phase 3 COLUMBUS trial of binimetinib and encorafenib in BRAF-mutant melanoma will be presented at the 2016 Society for Melanoma Research (SMR) Annual Congress in Boston, Massachusetts on November 9. Findings from COLUMBUS evaluating the combination of... |Plus d'articles...
- Major depressive disorder market will reach $5.8 billion by 2025 as awareness and drugs improve
- ABIVAX organise une journée R&D au sein de son laboratoire coopératif à Montpellier
- UAE pharmaceutical market set to hit $5.7 billion by 2020 as medical tourism grows
- Juntendo University research: Brain microcircuit for higher cognitive functions is identified